Apimeds Merges with MindWave to Integrate Biotech and AI Treasury Platforms
Reuters
Dec 17, 2025
Apimeds Merges with MindWave to Integrate Biotech and AI Treasury Platforms
Apimeds Pharmaceuticals US Inc. and MindWave Innovations Inc. have completed a merger that combines Apimeds' late-stage, non-opioid pain-management biologic portfolio with MindWave's AI-powered digital treasury infrastructure. The integration is supported by a $100 million PIPE commitment, enabling the newly formed entity to accelerate its development pipeline and enhance capital management through MindWave's AI-driven treasury engine. E.F. Hutton served as the exclusive M&A advisor and placement agent, coordinating transaction terms and the capital raise to support the combined company's strategic growth across biotech and digital asset management. This merger positions the business for long-term scalability by uniting biotech innovation with AI-based financial optimization. The announcement was made by E.F. Hutton.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apimeds Pharmaceuticals US Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9603424) on December 17, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.